These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 1638707)

  • 1. Electrocardiographic body surface mapping in patients with ventricular tachycardia. Assessment of utility in the identification of effective pharmacological therapy.
    Mitchell LB; Hubley-Kozey CL; Smith ER; Wyse DG; Duff HJ; Gillis AM; Horacek BM
    Circulation; 1992 Aug; 86(2):383-93. PubMed ID: 1638707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of magnetocardiographic QRST integral maps in the identification of patients at risk of ventricular arrhythmias.
    Hren R; Steinhoff U; Gessner C; Endt P; Goedde P; Agrawal R; Oeff M; Lux RL; Trahms L
    Pacing Clin Electrophysiol; 1999 Sep; 22(9):1292-304. PubMed ID: 10527010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of susceptibility to ventricular tachycardia after myocardial infarction by nondipolarity of QRST area maps.
    Tsunakawa H; Nishiyama G; Kusahana Y; Harumi K
    J Am Coll Cardiol; 1989 Nov; 14(6):1530-6. PubMed ID: 2809015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of quantitative body surface isoarea mapping for predicting ventricular tachyarrhythmias.
    Goldner BG; Horwitz L; Kohn N; Lesser M; Ehrlich J; Cohen TJ; Jadonath R
    Pacing Clin Electrophysiol; 1999 Mar; 22(3):453-61. PubMed ID: 10192854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordance between ambulatory monitoring and programmed stimulation in assessing efficacy of class IA antiarrhythmic agents in patients with ventricular tachycardia.
    Kim SG; Seiden SW; Matos JA; Waspe LE; Fisher JD
    J Am Coll Cardiol; 1985 Sep; 6(3):539-44. PubMed ID: 2411776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug response at electropharmacologic study in patients with ventricular tachyarrhythmias: the importance of ventricular refractoriness.
    Gillis AM; Wyse DG; Duff HJ; Mitchell LB
    J Am Coll Cardiol; 1991 Mar; 17(4):914-20. PubMed ID: 1999629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of combination therapy with mexiletine and a type IA agent for inducible ventricular tachyarrhythmias secondary to coronary artery disease.
    Greenspan AM; Spielman SR; Webb CR; Sokoloff NM; Rae AP; Horowitz LN
    Am J Cardiol; 1985 Aug; 56(4):277-84. PubMed ID: 4025166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arrhythmia vulnerability assessment using magnetic field maps and body surface potential maps.
    Stroink G; Meeder RJ; Elliott P; Lant J; Gardner MJ
    Pacing Clin Electrophysiol; 1999 Dec; 22(12):1718-28. PubMed ID: 10642124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The state of body surface mapping in Japan.
    Watanabe Y
    J Electrocardiol; 1995; 28 Suppl():110-20. PubMed ID: 8656097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of ventricular fibrillation versus monomorphic ventricular tachycardia during programmed stimulation. Role of premature beat conduction delay.
    Avitall B; McKinnie J; Jazayeri M; Akhtar M; Anderson AJ; Tchou P
    Circulation; 1992 Apr; 85(4):1271-8. PubMed ID: 1372847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The response to procainamide during electrophysiologic study for sustained ventricular tachyarrhythmias predicts the response to other medications.
    Waxman HL; Buxton AE; Sadowski LM; Josephson ME
    Circulation; 1983 Jan; 67(1):30-7. PubMed ID: 6847803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of antiarrhythmic efficacy of class I and III agents in patients with ventricular tachycardia by signal-averaged ECG analysis.
    Kulakowski P; Bashir Y; Heald S; Paul V; Anderson MH; Gibson S; Malik M; Camm AJ
    Pacing Clin Electrophysiol; 1992 Nov; 15(11 Pt 2):2116-21. PubMed ID: 1279610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiologic assessment of antiarrhythmic drug efficacy for ventricular tachyarrhythmias associated with dilated cardiomyopathy.
    Rae AP; Spielman SR; Kutalek SP; Kay HR; Horowitz LN
    Am J Cardiol; 1987 Feb; 59(4):291-5. PubMed ID: 3544793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective comparison of class IA, B, and C antiarrhythmic agents in combination with amiodarone in patients with inducible, sustained ventricular tachycardia.
    Toivonen L; Kadish A; Morady F
    Circulation; 1991 Jul; 84(1):101-8. PubMed ID: 1905591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate reproducibility of electrically induced sustained monomorphic ventricular tachycardia before and during antiarrhythmic therapy.
    Rosenbaum MS; Wilber DJ; Finkelstein D; Ruskin JN; Garan H
    J Am Coll Cardiol; 1991 Jan; 17(1):133-8. PubMed ID: 1987216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of antiarrhythmic drug effects by epinephrine: quinidine versus amiodarone.
    Calkins H; Sousa J; el-Atassi R; Schmaltz S; Kadish A; Morady F
    J Am Coll Cardiol; 1992 Feb; 19(2):347-52. PubMed ID: 1732363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent sustained ventricular tachycardia 3. Role of the electrophysiologic study in selection of antiarrhythmic regimens.
    Horowitz LN; Josephson ME; Farshidi A; Spielman SR; Michelson EL; Greenspan AM
    Circulation; 1978 Dec; 58(6):986-97. PubMed ID: 709782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrocardiographic correlates of spontaneous termination of ventricular tachycardia in patients with coronary artery disease.
    Duff HJ; Mitchell LB; Gillis AM; Sheldon RS; Chudleigh L; Cassidy P; Chiamvimonvat N; Wyse DG
    Circulation; 1993 Sep; 88(3):1054-62. PubMed ID: 8353867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of low-dose quinidine on ventricular tachyarrhythmias in patients with Brugada syndrome: low-dose quinidine therapy as an adjunctive treatment.
    Mizusawa Y; Sakurada H; Nishizaki M; Hiraoka M
    J Cardiovasc Pharmacol; 2006 Mar; 47(3):359-64. PubMed ID: 16633076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.
    Roden DM; Lee JT; Woosley RL; Echt DS
    Circulation; 1989 Nov; 80(5):1247-58. PubMed ID: 2805262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.